Viliami Fehoko

Edge Rusher

Age: 24
Free Agency: 2027 (UFA)
Accrued Seasons: 0
  • 2023 Salary Cap Charge: $922,689 (0.40% of cap)
  • 2023 Cash Payout: $1,440,756 (0.56% of spending)
  • 2023 Cash to Cap Ratio: 1.56
  • Contract Value: $4,530,756 ($1,132,689 APY)
  • Fully Guaranteed Money: $690,756
  • Contract Ranking: 128/222 at EDGE

Current Contract

(Drafted, signed 2023)
(📝: indicates contract trigger occuring during that year)
YearAgeBase SalaryProrated BonusCap
Cap %
Dead Money & Cap Savings

Contract Notes

Viliami Fehoko signed a four year contract worth $4,530,756 with the Cowboys on May 12, 2023. The contract has $690,756 in guarantees. He received a signing bonus worth $690,756.

Cash Flows

- fully earned money
- unearned or partially earned money
Cash Due$1,440,756$915,000$1,030,000$1,145,000
Running Cash$1,440,756$2,355,756$3,385,756$4,530,756
Career Earnings: $690,756
Career APY: $0
Potential Earnings: $4,530,756
Total Guarantees: $690,756
Largest Cash Payment: $1,440,756 (2023)
Largest Cap Number: $1,317,689 (2026)

Contract History

TeamContract TypeStatusYear SignedYrsTotalAPYGuaranteesAmount Earned% EarnedEffective APY
Earnings By Team
TeamYrsSalaryAPYPaid on Cap% Paid on CapPaid as Dead Money% Paid as Dead Money


No statistics available.

Valuation Diamond

The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.

OTC ValuationAPY
Injury Adjusted$0$0
OTC Valuation $5.7M $11.5M $17.2M $23M $28.7M APY $5.7M $11.3M $17M $22.7M $28.3M $11,057,000 $8,000,000

Weekly Valuation Trends

The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.

To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.